ECSP045098A - Procedimientos para tratar enfermedades neovasculares oculares - Google Patents

Procedimientos para tratar enfermedades neovasculares oculares

Info

Publication number
ECSP045098A
ECSP045098A EC2004005098A ECSP045098A ECSP045098A EC SP045098 A ECSP045098 A EC SP045098A EC 2004005098 A EC2004005098 A EC 2004005098A EC SP045098 A ECSP045098 A EC SP045098A EC SP045098 A ECSP045098 A EC SP045098A
Authority
EC
Ecuador
Prior art keywords
procedures
treating eye
neovascular diseases
eye neovascular
treating
Prior art date
Application number
EC2004005098A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045098A publication Critical patent/ECSP045098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a procedimientos para tratar la neovascularización ocular usando agentes que inhiben el VEGF.
EC2004005098A 2001-11-09 2004-05-07 Procedimientos para tratar enfermedades neovasculares oculares ECSP045098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33230401P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
ECSP045098A true ECSP045098A (es) 2004-07-23

Family

ID=23297643

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005098A ECSP045098A (es) 2001-11-09 2004-05-07 Procedimientos para tratar enfermedades neovasculares oculares

Country Status (26)

Country Link
US (3) US20030171320A1 (es)
EP (1) EP1441743A4 (es)
JP (1) JP2005511576A (es)
KR (1) KR20050044372A (es)
CN (1) CN1582156A (es)
AP (1) AP1750A (es)
AR (1) AR037307A1 (es)
BR (1) BR0213975A (es)
CA (1) CA2464007A1 (es)
CR (1) CR7330A (es)
EA (1) EA006746B1 (es)
EC (1) ECSP045098A (es)
GE (1) GEP20063755B (es)
HR (1) HRP20040406A2 (es)
IL (1) IL161327A0 (es)
IS (1) IS7215A (es)
MA (1) MA27145A1 (es)
MX (1) MXPA04004363A (es)
NO (1) NO20041882L (es)
OA (1) OA12720A (es)
PL (1) PL371929A1 (es)
RS (1) RS35404A (es)
TN (1) TNSN04081A1 (es)
TW (1) TWI260327B (es)
WO (1) WO2003039404A2 (es)
ZA (1) ZA200402753B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
US20060231107A1 (en) * 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
EP1732571A4 (en) * 2004-03-05 2009-09-09 Archemix Corp CONTROLLED MODULATION OF PHARMACOKINETICS AND BIODISTRIBUTION OF APTAMER THERAPEUTICS
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
MXPA06014092A (es) * 2004-06-04 2007-03-15 Scripps Research Inst Composiciones y metodos para el tratamiento de enfermedades neovasculares.
US7785784B2 (en) * 2004-07-23 2010-08-31 Eyetech, Inc. Detection of oligonucleotides by dual hybridization
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
PT1802334E (pt) * 2004-10-21 2012-11-28 Genentech Inc Método para tratamento de doenças neovasculares intraoculares
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2006047716A2 (en) * 2004-10-26 2006-05-04 Bioresponse Llc Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2602525A1 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
US20090281184A1 (en) * 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2622312A1 (en) * 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
KR101478164B1 (ko) * 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US20070248646A1 (en) * 2006-02-16 2007-10-25 Ali Hafezi-Moghadam Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
CA2654510C (en) * 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
WO2008103320A1 (en) * 2007-02-16 2008-08-28 Novacea, Inc. Methods of treating ophthalmic disorders with anthraquinones
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
JP5988584B2 (ja) 2008-12-16 2016-09-07 キュー エル ティー インク．ＱＬＴ Ｉｎｃ． 眼の状態に関する光線力学的療法
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
ES2468827T3 (es) * 2010-01-14 2014-06-17 Sanwa Kagaku Kenkyusho Co., Ltd Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2012105610A1 (ja) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
KR101303920B1 (ko) * 2011-04-26 2013-09-05 서울대학교산학협력단 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물
TW201406707A (zh) * 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013100070B4 (en) * 2012-07-03 2013-04-04 Novartis Ag Use of device
CN103721257B (zh) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
RU2527360C1 (ru) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ комбинированного лечения ретиноваскулярного макулярного отека
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
EP3086809A4 (en) * 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
KR20180090785A (ko) 2015-10-07 2018-08-13 아펠리스 파마슈티컬스 인코포레이티드 투여 요법
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
BR112019020955A2 (pt) 2017-04-07 2020-05-05 Apellis Pharmaceuticals, Inc. regimes de dosagem e composições e métodos relacionados
DE102017008721A1 (de) 2017-09-16 2019-03-21 protectismundi GmbH Verfahren und Vorrichtung zur Hochhausbrandbekämfpung
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
JP2021507884A (ja) 2017-12-15 2021-02-25 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113101530B (zh) * 2021-04-14 2022-09-30 中国人民解放军陆军特色医学中心 一种通过无线充电激活玻璃体腔植入性发光二极管的系统
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20240121668A (ko) 2023-02-01 2024-08-09 아주대학교산학협력단 염증성 눈질환의 예방 및 치료용 조성물
WO2024243081A1 (en) * 2023-05-19 2024-11-28 The Trustees Of Columbia University In The City Of New York Treating elevated intraocular pressure with nicotinamide
CN118108804B (zh) * 2024-04-26 2024-06-25 山东大学 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
JP3845469B2 (ja) * 1996-02-21 2006-11-15 明治製菓株式会社 眼底の新生血管の閉塞に用いる投与剤
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
CA2398901C (en) * 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2373237A1 (en) * 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
HUP0300347A3 (en) * 2000-03-24 2005-03-29 Novartis Ag Improved treatment of neovascularization
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
US20030171320A1 (en) 2003-09-11
AP1750A (en) 2007-06-23
MXPA04004363A (es) 2005-05-16
OA12720A (en) 2006-06-27
WO2003039404A2 (en) 2003-05-15
TNSN04081A1 (fr) 2006-06-01
JP2005511576A (ja) 2005-04-28
EP1441743A2 (en) 2004-08-04
EP1441743A4 (en) 2009-02-25
KR20050044372A (ko) 2005-05-12
EA200400518A1 (ru) 2004-12-30
EA006746B1 (ru) 2006-04-28
IL161327A0 (en) 2004-09-27
TW200302226A (en) 2003-08-01
PL371929A1 (en) 2005-07-11
GEP20063755B (en) 2006-02-27
RS35404A (sr) 2006-10-27
NO20041882L (no) 2004-05-07
US20040167091A1 (en) 2004-08-26
WO2003039404A3 (en) 2004-02-12
AR037307A1 (es) 2004-11-03
TWI260327B (en) 2006-08-21
CA2464007A1 (en) 2003-05-15
CN1582156A (zh) 2005-02-16
US20070027101A1 (en) 2007-02-01
AP2004003026A0 (en) 2004-06-30
ZA200402753B (en) 2005-01-05
HRP20040406A2 (en) 2005-02-28
BR0213975A (pt) 2005-05-10
MA27145A1 (fr) 2005-01-03
CR7330A (es) 2005-06-15
IS7215A (is) 2004-04-07

Similar Documents

Publication Publication Date Title
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
AR061757A1 (es) Lentes oftalmologicas multifocales de transicion gradual
DK1660057T3 (da) Kombinationsterapi til behandling af neovaskulære øjenlidelser
MA31907B1 (fr) Nouveaux herbicides
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
EP1383532A4 (en) Combination therapy
UY27695A1 (es) Compuestos que modulan la actividad de ppar.
GT200300054A (es) Compuestos que modulan la actividad de ppar
GT200300053A (es) Compuestos que modulan la actividad de ppar
BRPI0417006A (pt) administração intraóssea local de agentes de formação de osso e agentes anti-reabsorção e dispositivos para a mesma
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
NO20034056D0 (no) Proliferative sykdommer
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
MXPA06014470A (es) Formulaciones oftalmicas que incluyen antagonistas de alfa 1 selectivas.
CR8701A (es) Moduladores canabinoides de tetrahidro-indazol
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
CR10414A (es) Tratamientos de las alergias oculares
ECSP044981A (es) Composicion oftalmica que comprende ascomicina
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
TW200603828A (en) Treatment of disorders
PL359027A1 (pl) Udoskonalone leczenie neowaskularyzacji
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
EP4294925A4 (en) Ube3a antisense therapeutics
FI20030779A0 (fi) Matriisinauha